In 2026, BioPhotas, Inc., the makers of Celluma Light Therapy, proudly celebrates 15 years of pioneering innovation, marking a milestone that reflects both a legacy of scientific advancement and a bold step into the future.
Since its inception, Celluma has challenged the status quo of light therapy. At a time when devices were often rigid, expensive, and limited in application, the company introduced a breakthrough: a flexible, shape-taking LED device capable of treating multiple conditions across the face and body. This innovation not only redefined usability but also leveraged the principles of optical physics to deliver light energy more efficiently and effectively at an affordable price.
Milestones That Defined a Category
From the very beginning, Celluma has been at the forefront of industry evolution. Key milestones include:
- 2011: Launch of the Celluma PRO — a flagship device that quickly became a clinical gold standard for multi-mode LED therapy.
- 2013: First-of-its-kind innovation — the first flexible LED device to receive FDA clearance for multiple indications within a single system.
- 2014: Researchers from the Beckman Laser Institute at the University of California publish multiple peer-reviewed studies using the Celluma to definitively identify the fundamental mechanism of action at play in LLLT and demonstrate that an LED device is equally efficacious as a surgical laser to promote cell proliferation and cell migration in dermal wound healing. The Celluma LITE, a smaller version of the Celluma PRO, is introduced.
- 2015: U.S. and International patents are granted related to the novelty of the Celluma's flexible and shape-taking characteristics.
- 2016: The Celluma is Medical CE-Marked for all of its FDA-cleared indications-for-use and becomes the first LLLT device to be Medical CE-marked for Dermal Wound Healing.
- 2017: The Celluma receives FDA-clearance for treating “full-face wrinkles on an over-the-counter basis. All of the Celluma’s indications-for-use have been granted on an OTC basis in the U.S. and for at-home use in the U.K. and E.U.
- 2019: The Celluma PRO receives the coveted Aesthetics Award for "Product Innovation of the Year," beating out all other products in the U.K. medical aesthetic market, not just light therapy devices.
- 2021: The Celluma RESTORE is the first LED device to be FDA-cleared for hair restoration, aging skin, as well as a variety of pain conditions in a single device.
- 2022: The Celluma RESTORE is approved for the UK aesthetic market. National Celluma Light Therapy Day is established on June 20th.
- 2023: Celluma expands its corporate headquarters and moves from Anaheim back to Tustin, California, allowing the company to increase production and streamline shipping operations to keep pace with increased domestic and international sales.
- 2024: Celluma announces its sixth FDA 510(k) clearance with the introduction of the Celluma CONTOUR for body contouring, the company's first multi-panel device.
- 2025: Celluma introduces its second-generation technology that are battery powered and include a new micro-processor, expanding the current and future capability of the entire product line. Celluma launches the Series 2 DELUX adding a 4th mode for body contouring. Celluma introduces a redesigned handheld POD that is rechargeable and also adds body contouring mode. Celluma launches PRO PLUS, CONTOUR PLUS, and NOVA, the first 5-mode device on the market for OTC use.
Today, with nearly 200,000 devices in clinical use worldwide and a portfolio spanning 14-models—all designed and manufactured in the USA—Celluma continues to lead the evolution of light therapy, supporting skin health, pain management, hair restoration, body contouring, and overall wellness.
Throughout its growth, Celluma has remained profitable, debt-free, and cash-flow positive for over a decade—delivering a cumulative 10x return to shareholders while continually reinvesting in top talent and product innovation.
A Legacy of Impact and What Comes Next For Celluma
More than a product story, Celluma’s growth reflects a broader impact: helping practitioners expand their businesses, improving patient outcomes, and making clinically effective light therapy more accessible to people around the world.
Now, as the company celebrates its 15th anniversary, it is preparing to unveil its latest innovation, signaling the next chapter in light therapy.
To mark the occasion, BioPhotas will host an exclusive live Fireside Chat on April 16 at 10:30 AM PDT, featuring Founder Patrick Johnson in conversation with industry expert Barry Eichner of Lipgloss + Aftershave. Attendees will receive a first look at the new product, along with insights into the evolution of light therapy and where the category is headed next.
“This marks a pivotal moment for our company,” said Curtis Cluff, CEO of BioPhotas, Inc. “For 15 years, we’ve led the evolution of light therapy with devices designed for both clinical and home use. What we’re unveiling next reflects not only where we’ve been, but where this category is going.”
Be the First to See What’s Next
Attendees of the Fireside Chat will:
- Hear directly from the company’s founder about the future of light therapy.
- Gain insights from leading voices in the industry.
- Experience an exclusive first look at Celluma’s newest innovation.
- Be entered into a special live promotional giveaway.
As Celluma looks ahead, one thing remains clear: innovation is not just part of its history—it is the path forward.
Register now to reserve your spot: Register for the BIG Reveal Event & Fireside Chat | Celluma Light Therapy
